His case was considered a milestone for #MeToo, in which women accused hundreds in entertainment, media, politics and other fields of sexual misconduct
The trial, which could include many thousands of patients in dozens of countries, has been designed to be as simple as possible so that even hospitals overwhelmed by an onslaught of COVID-19 patients can participate, according to the prestigious journal Science.
Scientists have suggested dozens of existing compounds for testing but WHO is focusing on what it says are the four most promising therapies.
These are "an experimental antiviral compound called remdesivir; the malaria medications chloroquine and hydroxychloroquine; a combination of two HIV drugs, lopinavir and ritonavir; and that same combination plus interferon-beta, an immune system messenger that can help cripple viruses," said the article in the journal of the American Association for the Advancement of Science (AAAS).
All in all, more than 20 COVID-19 studies in China used chloroquine or hydroxychloroquine, WHO notes, but their results have been hard to come by.
"WHO is engaging with Chinese colleagues at the mission in Geneva and have received assurances of improved collaboration; however, no data has been shared regarding the chloroquine studies."
Researchers in France have published a study in which they treated 20 COVID-19 patients with hydroxychloroquine. They concluded that the drug significantly reduced viral load in nasal swabs. But it was not a randomized controlled trial and it didn't report clinical outcomes such as deaths.
"Hydroxychloroquine in particular might do more harm than good. The drug has a variety of side effects and can in rare cases harm the heart," said the Science article.
Ritonavir/lopinavir combination drug, sold under the brand name Kaletra, was approved in the US in 2000 to treat HIV infections.
The first trial with COVD-19 was not encouraging, however. Doctors in Wuhan, China, gave 199 patients two pills of lopinavir/ritonavir twice a day plus standard care, or standard care alone.
There was no significant difference between the groups, they reported in the New England Journal of Medicine (NEJM) on March 15.
"But the authors caution that patients were very ill -- more than a fifth of them died -- and so the treatment may have been given too late to help."
Ritonavir/lopinavir+interferon beta is an another option. A combination of the three drugs is now being tested in MERS patients in Saudi-Arabia in the first randomized controlled trial for that disease.
His case was considered a milestone for #MeToo, in which women accused hundreds in entertainment, media, politics and other fields of sexual misconduct
Well-known communication expert Maha Abouelenein on what it takes to thrive in the age of social media
From cultural events, and culinary delights to outdoor adventures, here's a line-up of thrilling activities to make your weekend exciting
'The rom-com garnered $219 million worldwide after its premiere in December
The guitar will be auctioned on May 29 at the Hard Rock Cafe in New York
Fitness enthusiast Sarah Lindsay shares insights on what it takes to embark on a fitness journey and sustain it amidst a busy lifestyle
Such platforms help women to re-enter the workforce by equipping them with new-age skills, upskilling, polishing their interviewing skills and revamping their resumes
Official autism-friendly in-flight certification is in the works, possibly used by other airlines